The general principles of neural transplantation are now fairly well established, as a result of experience with transplanting many different regions of the central nervous system (eNS). A major stimulus to this work has been the finding that some of the symptoms of Parkinson's disease can be improved by grafts of embryonic substantia nigra, and many of the basic rules of transplantation have come out of the development of this procedure. In general only embryonic nervous tissue will survive transplantation, and this must be removed from the embryo during a narrow time window corresponding with the time at which the neurons in question have just undergone their final cell division. The transplanted neurons can grow processes into the host eNS, and make functional synaptic connections with host neurons. Similarly, host neuronal processes can sprout or regenerate into the transplant and make synapses with grafted neurons. The limita tion, however, is that axons from the graft will not grow for appreciable distances into the host eNS unless there are target neurons immediately adjacent to the graft. In the case of substantia nigra grafts, for instance, if the graft is placed within the host substantia nigra, its axons will not grow through the host brain to their correct target in the striatum, they will only make local contacts. In order, therefore, to have an effect in Parkinson's disease, grafts must be placed heterotopic ally within the striatum, so that their axons can grow out and make connections, 1-4 The extent of the connections made by grafts is very dependent on the age of the host. Grafts placed into newborn hosts, whose eNS has not yet become inhibitory to axon growth, grow axons extensively, and also receive a profuse axonal projection from the host neurons. However, as animals age, the glial environment of their eNS becomes inhibitory to axon growth, and the regenerative ability of their neurons decreases, and this is reflected in a diminution of connections to and from a graft of embryonic eNS tissue.5,6 Embryonic grafts, therefore, can in favourable circumstances replace the function of lost neurons. However, before they become useful for the treatment of most eNS disorders there are several practical problems which will need to be solved. These are (1) that a large proportion of grafted neurons may die soon after transplantation (around 97% in the case of substantia nigra transplants); (2) that axons from the grafts will not grow for long distances through non-target regions of the host eNS; 
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In addition to embryonic neuronal grafts, there has been a considerable body of work on grafts specifically designed to encourage axon regeneration in the damaged cord. Almost all this work has focused on Schwann cells, since it is these cells which support axon regeneration in peripheral nerves and since implanted Schwann cells have been shown to promote regenera tion of adult CNS axons. The most concerted effort in this direction has come from workers in the Miami Project to Cure Paralysis. They have been able to greatly expand Schwann cell numbers in tissue culture, then place them in a semi-permeable tube which is inserted into the damaged dorsal columns. Very large numbers of axons will regenerate into these grafts, but the problem remains that the regenerating axons show very little ability to leave the grafts and grow on into the spinal cord to make useful functional connections. 15
This technology will therefore have to be combined with techniques to make the environment of the adult spinal cord less inhibitory to axon regeneration before function can be restored using these techniques. Em bryonic spinal cord tissue may also act as a bridge to allow axons to regenerate across a lesion, but again these axons only progress beyond the bridge if the host is a newborn animal.
Spinal cord grafts have just started to reach the stage where they can reconstruct some of the circuitry in the damaged cord in experimental animals, with some behavioural benefit. The technology is barely ready for human patients, although some transplants have been performed in Russia, and limited improvement is reported over two to five spinal levels.7 However, from experience in Parkinson's disease one can predict that grafts are very unlikely to do any harm, and therefore experimental trials might be expected sooner rather than later. Will grafts ever be of benefit to the spinally injured patient? With the technology available now, and likely to become available in the next few years, the axonal connections made as a result of spinal cord grafting are likely to be restricted to the regions within a centimetre of the graft, and therefore effects will be local. However, there are many patients with high cervical lesions whose hand function might be greatly improved by regaining control of an extra spinal level or two. Effects on the rest of the cord might come from remyelination of the many locally demyelinated axons seen in most partial cord lesions, but the extent to which this can be achieved has yet to be established.
